Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

被引：0
|
作者：
Javian C. Malcolm
Nadia Falzone
Jennifer E. Gains
Matthew D. Aldridge
David Mirando
Boon Q. Lee
Mark N. Gaze
Katherine A. Vallis
机构：
[1] University of Oxford,Oxford Institute for Radiation Oncology
[2] University College London Hospitals NHS Foundation Trust,Department of Oncology
[3] University College London Hospitals NHS Foundation Trust,Institute of Nuclear Medicine
[4] MIM Software,undefined
来源：
EJNMMI Physics | / 9卷
关键词：
[; Lu]Lu-DOTATATE; Dosimetry; Inter-cyclic changes; Pharmacokinetics; Peptide receptor radionuclide therapy; Neuroblastoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] 177Lu Dotatate vs. Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit
    Page, E.
    Tipping, J.
    Birch, E.
    Hamilton, D.
    Manoharan, P.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 137 - 138
  • [32] Radiation Safety Observations Associated with 177Lu Dotatate Patients
    Nelson, Kevin L.
    Sheetz, Michael A.
    HEALTH PHYSICS, 2019, 117 (06): : 680 - 687
  • [33] Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines
    Delbart, Wendy
    Ghanem, Ghanem E.
    Karfis, Ioannis
    Flamen, Patrick
    Wimana, Zena
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 96-97 : 68 - 79
  • [34] [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy–associated myeloid neoplasms: insights from the WHO pharmacovigilance database
    Jonathan Vigne
    Basile Chrétien
    Anne-Laure Bignon
    Karine Bouhier-Leporrier
    Charles Dolladille
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3332 - 3333
  • [35] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Sejin Ha
    Yong-il Kim
    Jungsu S. Oh
    Changhoon Yoo
    Baek-Yeol Ryoo
    Jin-Sook Ryu
    EJNMMI Physics, 11
  • [36] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Ha, Sejin
    Kim, Yong-il
    Oh, Jungsu S.
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Ryu, Jin-Sook
    EJNMMI PHYSICS, 2024, 11 (01)
  • [37] Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice
    Svensson, Johanna
    Molne, Johan
    Forssell-Aronsson, Eva
    Konijnenberg, Mark
    Bernhardt, Peter
    NUCLEAR MEDICINE AND BIOLOGY, 2012, 39 (06) : 756 - 762
  • [38] Incidental Visualization of Gallbladder on Post-therapy [177Lu]Lu-DOTATATE Scintigraphy Mimicking a Liver Metastasis in a Duodenal Neuroendocrine Tumor
    Baberwal, Parth
    Parghane, Rahul
    Basu, Sandip
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2024, 23 (04) : 292 - 294
  • [39] Lutadose Trial: the impact on treatment outcomes of dosimetry after the first administration of [177Lu]Lu-DOTATATE in gastro-entero-pancreatic neuroendocrine neoplasms (GEP NENs) patients
    Cuomo, M.
    Bauckneht, M.
    Bagnalasta, M.
    Mazzaglia, S.
    Scalorbi, F.
    Argiroffi, G.
    Kirienko, M.
    Lorenzoni, A.
    Pusceddu, S.
    Calaresu, G.
    Garanzini, E.
    Coppa, J.
    Chiesa, C.
    Maccauro, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S247 - S247
  • [40] Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
    Bodei, Lisa
    Cremonesi, Marta
    Ferrari, Mahila
    Mittra, Erik S.
    Kulkarni, Harshad R.
    Deroose, Christophe M.
    Srirajaskanthan, Rajaventhan
    Ramage, John
    Grana, Chiara Maria
    Botta, Francesca
    Weber, Matthias M.
    Miederer, Matthias
    Reddy, Ryan
    Chicco, Daniela
    Mariani, Maurizio F.
    Demange, Arnaud
    Erion, Jack L.
    Gericke, Germo
    Krenning, Eric
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (03) : 449 - 456
12345